Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00326612 · ClinicalTrials.gov registry record · Phase 2

Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures

A Phase 2 study of Seizures, sponsored by University of Utah.

Completed
Registry status
Phase 2
Development phase
358
Enrollment target
1
Study location

NCT00326612: Completed Phase 2 study of Seizures, sponsored by University of Utah.

NCT00326612 is a Phase 2 study of Seizures that has completed, run by University of Utah. The registered enrollment target is 358 participants, below the 925-participant average among 39 other Seizures trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00326612, a Phase 2 study of Seizures, has completed, sponsored by University of Utah.

COMPLETED
Registry status
Phase 2
Development phase
358 participants
Enrollment target
1
Study location

Study Summary

The investigators will conduct a randomized controlled trial comparing the use of nasal midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute seizure activity in children under the age of 18 years with epilepsy in the community setting. The primary hypothesis is that nasal midazolam will be more effective and have shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses are that patients treated with nasal midazolam will have fewer respiratory complications, emergency department visits, and admissions.

Primary Outcome

Length of seizure.

Conditions Studied

Interventions

  • DRUG Midazolam
  • DRUG Diazepam

Study Locations (1)

Utah

  • Primary Children's Medical Center - Salt Lake City

Trial Details

FieldValue
Enrollment Target 358 participants
Start Date 2006-06
Est. Completion 2008-12
Phase Phase 2
University of Utah

818 total trials

What the finished NCT00326612 record still lists

NCT00326612 is an interventional study that assigns participants to a tested intervention. The registered 358 participants enrollment target is mid-sized for trials with a published cap, below the 925-participant average among 39 other Seizures trials with a reported enrollment target (61% lower).

The record links to 1 condition, with Seizures appearing as the primary indexed condition, and to 2 interventions - of which Midazolam is the first listed.

NCT00326612 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT00326612 about?

NCT00326612 is a clinical study titled "Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures". The investigators will conduct a randomized controlled trial comparing the use of nasal midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute seizure activity in children under the age of 18 years with epilepsy in the community setting. The primary hypothesis i...

What is the current status of trial NCT00326612?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 358 participants. The study started on 2006-06. Estimated completion is 2008-12.

What conditions does trial NCT00326612 study?

This clinical trial studies the following conditions: Seizures.

What interventions are being tested in trial NCT00326612?

The interventions under investigation include: Midazolam (DRUG), Diazepam (DRUG).

Who is sponsoring clinical trial NCT00326612?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00326612 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Seizures

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00326612's enrollment target sits among peer trials

358 10th of 39 higher than 30 of 39 other Seizures trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Seizures trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04373317 · 358 participants · Phase 4

    Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

  • NCT05684965 · 358 participants · Phase 1

    XTX301 in Patients With Advanced Solid Tumors

  • NCT05824975 · 358 participants · Phase 1

    A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

  • NCT06480227 · 358 participants · NA

    Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00326612, the US trial registry maintained by the National Library of Medicine. NCT00326612 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.